Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14192040 | 1.00 | CFTR (0.39) | CFTRMAPK1CCR2KCNH2DGAT2 | |
| SCHEMBL14192037 | 0.92 | CFTR (0.45) | CFTRMAPK1SSTR5 | |
| SCHEMBL5107473 | 0.92 | CFTR (0.45) | CFTRMAPK1SSTR5 | |
| SCHEMBL5106760 | 0.89 | CFTR (0.39) | CFTRMAPK1CCR2KCNH2DGAT2 | |
| SCHEMBL14192043 | 0.89 | CFTR (0.39) | CFTRMAPK1CCR2KCNH2DGAT2 | |
| SCHEMBL5104284 | 0.88 | LMNA (0.41) | CFTRDGAT2PPARA | |
| SCHEMBL14192033 | 0.88 | LMNA (0.41) | CFTRDGAT2PPARA | |
| SCHEMBL14192039 | 0.88 | CFTR (0.38) | CFTRMAPK1EGLN1SSTR5CRHR1 | |
| SCHEMBL5112424 | 0.88 | CFTR (0.38) | CFTRMAPK1EGLN1SSTR5CRHR1 | |
| SCHEMBL14192034 | 0.83 | EPHX2 (0.41) | CFTRDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | CFTR 4732/4885MAPK1 2084/4885CCR2 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.